Pfizer (PFE)Director bought ~$499K

~$499K

Approx. value · 19K sh @ $25.65

28K

Holds after · shares reported

Traded

Feb 13, 2025

Filed

Feb 14, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Dec 20, 2024FDAFDA drug approval: Braftovi
2. Dec 20, 2024Layoff notice · Heights Union East, 2002 N. 6th Floor, TAMPA, FL, 33602Layoff notice filed in FL: 62 employees
3. Jan 15, 2025CongressDisclosed partial sale of PFE — reported range $1,001 - $15,000
4. Jan 24, 2025CongressDisclosed partial sale of PFE — reported range $1,001 - $15,000
5. Jan 31, 2025FDAFDA drug approval: Paxlovid (Copackaged)
6. Feb 12, 2025CongressDisclosed sale of PFE — reported range $1,001 - $15,000
7. Feb 13, 2025 · this disclosureInsiderDirector purchased ~$499K of PFE shares in the open market

What came next

1. Feb 13, 2025CongressDisclosed sale of PFE — reported range $1,001 - $15,000
2. Feb 21, 2025FDAFDA drug approval: Xeljanz
3. Feb 21, 2025FDAFDA drug approval: Xeljanz XR
4. Feb 24, 2025CongressDisclosed purchase of PFE — reported range $15,001 - $50,000
5. Feb 25, 2025CongressDisclosed purchase of PFE — reported range $15,001 - $50,000
6. Feb 26, 2025CongressDisclosed purchase of PFE — reported range $1,001 - $15,000
7. Mar 3, 2025CongressDisclosed purchase of PFE — reported range $1,001 - $15,000
8. Mar 4, 2025InsiderOfficer sold ~$65K of PFE shares in the open market
9. Mar 10, 2025CongressDisclosed sale of PFE — reported range $1,001 - $15,000
10. Mar 12, 2025FDAFDA drug approval: Mektovi
11. Mar 12, 2025FDAFDA drug approval: Braftovi
12. Mar 31, 2025Congress · 1 personMembers of Congress: 2 sales
13. Apr 8, 2025CongressDisclosed sale of PFE — reported range $15,001 - $50,000
14. Apr 11, 2025CongressDisclosed sale of PFE — reported range $15,001 - $50,000
15. Apr 21, 2025CongressDisclosed sale of PFE — reported range $1,001 - $15,000
16. Apr 23, 2025FDAFDA drug approval: Ibrance
17. Apr 23, 2025FDAFDA drug approval: Ibrance
18. Apr 29, 2025CongressDisclosed purchase of PFE — reported range $1,001 - $15,000
19. May 15, 2025CongressDisclosed purchase of PFE — reported range $15,001 - $50,000
20. May 28, 2025FDARecall: DOBUTamine Injection, USP, 250 mg/20 mL (12.5 mg/mL), 20 mL per Single-dose Vial, carton of 10 Fliptop Vials, Rx only, For Intravenous Use Only, Made in Italy,…

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Pfizer

For Pfizer, OQRO holds 4 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports and 54 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PFE page.

Other recent filings by Ronald E Blaylock, Director

• SEC Form 4 at Pfizer (PFE)Aug 5, 2026

The full history of Ronald E Blaylock, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Pfizer

• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026

Everything OQRO holds on this company is on its PFE page.